1197-18-8

  • Product Name:Tranexamic acid
  • Molecular Formula:C8H15NO2
  • Purity:99%
  • Molecular Weight:
Inquiry

Product Details

Appearance:white crystalline powder

High Purity Tranexamic acid 1197-18-8 for sale, Good Supplier In China

  • Molecular Formula:C8H15NO2
  • Molecular Weight:157.213
  • Appearance/Colour:white crystalline powder 
  • Vapor Pressure:0mmHg at 25°C 
  • Melting Point:300 °C 
  • Refractive Index:1.497 
  • Boiling Point:300.201 °C at 760 mmHg 
  • PKA:pKa 4.3 (Uncertain);10.6 (Uncertain) 
  • Flash Point:135.357 °C 
  • PSA:63.32000 
  • Density:1.096 g/cm3 
  • LogP:1.53640 

Good producer Hot Sale Top quality 1197-18-8 Tranexamic acid

Tranexamic acid (TXA) was invented by Japanese scientists Shosuke and Utako Okamoto shortly after World War II. TXA is an antifibrinolytic drug that reduces bleeding by inhibiting the enzymatic breakdown of fibrin blood clots. Plasminogen, a glycoprotein pro-enzyme produced in the liver, is converted into the fibrinolytic enzyme plasmin by tissue plasminogen activator (tPA). The plasminogen molecule is folder into loops called kringles that protrude like fingers. These fingers bind to fibrin via lysine-binding sites on their tips. If the lysine residues on fibrin are enzymatically removed, plasminogen binding is inhibited. Fibrin binds both plasminogen and tPA which localizes and promotes plasmin production. Plasmin that is bound to fibrin is shielded from plasmin inhibitors. Plasmin cuts fibrin into fibrin degradation products. This exposes more lysine molecules which bind more plasminogen, thus accelerating fibrinolysis. TXA has a molecular structure similar to lysine and inhibits fibrinolysis by inhibiting the binding of plasminogen to fibrin.

Among patients with bleeding trauma, the use of tranexamic acid, a fibrinolysis inhibitor, was associated with a significant reduction in overall mortality. Similar results have been reported in patients with traumatic brain injury and established obstetrical hemorrhage.

 

Shanghai Upbio Tech Co.,Ltd (Former Onchem (China)Co.,Ltd), a good producer hot sale top quality 1197-18-8 Tranexamic acid, is a comprehensive manufacturer and an international distribution of chemicals throughout the world,  The predecessor of Shanghai Upbio Tech Co.,Ltd was Onchem (China) Co.,Ltd in 2010,Specialized in APIs, chemical intermediates, herbal extract and pharmaceutical raw materials. We have our own GMP factory with R&D centure.and cleaning workshop , and some main products produced by our own lab and R&D centure.besides we have established very good cooperation and business relations with hundreds of Chinese qualified manufacturers by long-term business intercourse.

 

InChI:InChI=1/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-

1197-18-8 Relevant articles

The effect of intravenous unit-dose tranexamic acid on visible and hidden blood loss in posterior lumbar interbody fusion: a randomized clinical trial

Shenshen Hao, Hongke Li, Shuai Liu, Saike Meng, Xiaopeng Zhang, Linfei Wang, Hongjie Yang, Liyan Zhang & Shengli Dong

Scientific Reports volume 13, Article number: 4714 (2023)

Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that inhibits plasminogen, fibrinolysis and tissue plasminogen activator binding by competing for lysine binding sites. Thereby delaying fibrinolysis and blood clot degradation, TXA achieves the purpose of reducing intraoperative bleeding.

Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery

Luis D. Pacheco, M.D., Rebecca G. Clifton, Ph.D., George R. Saade, M.D., Steven J. Weiner, M.S., Samuel Parry, M.D., John M. Thorp, Jr., M.D., Monica Longo, M.D., Ph.D., Ashley Salazar, R.N., M.S.N., W.H.N.P., Wendy Dalton, R.N., Alan T.N. Tita, M.D., Ph.D., Cynthia Gyamfi-Bannerman, M.D., Suneet P. Chauhan, M.D., Torri D. Metz, M.D., Kara Rood, M.D., Dwight J. Rouse, M.D., Jennifer L. Bailit, M.D., M.P.H., William A. Grobman, M.D., Hyagriv N. Simhan, M.D., and George A. Macones, M.D

April 13, 2023 N Engl J Med 2023; 388:1365-1375

A total of 11,000 participants underwent randomization (5529 to the tranexamic acid group and 5471 to the placebo group); scheduled cesarean delivery accounted for 50.1% and 49.2% of the deliveries in the respective groups.

Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery

Luis D. Pacheco, M.D., Rebecca G. Clifton, Ph.D., George R. Saade, M.D., Steven J. Weiner, M.S., Samuel Parry, M.D., John M. Thorp, Jr., M.D., Monica Longo, M.D., Ph.D., Ashley Salazar, R.N., M.S.N., W.H.N.P., Wendy Dalton, R.N., Alan T.N. Tita, M.D., Ph.D. Cynthia Gyamfi-Bannerman, M.D., Suneet P. Chauhan, M.D., Torri D. Metz, M.D., Kara Rood, M.D., Dwight J. Rouse, M.D., Jennifer L. Bailit, M.D., M.P.H., William A. Grobman, M.D., Hyagriv N. Simhan, M.D., and George A. Macones, M.D.

N Engl J Med 2023;388:1365-1375

A total of 11,000 participants underwent randomization (5529 to the tranexamic acid group and 5471 to the placebo group); scheduled cesarean delivery accounted for 50.1% and 49.2% of the deliveries in the respective groups. A primary-outcome event occurred in 201 of 5525 participants (3.6%) in the tranexamic acid group and in 233 of 5470 (4.3%) in the placebo group (adjusted relative risk, 0.89; 95.26% confidence interval [CI], 0.74 to 1.07; P=0.19). Estimated intraoperative blood loss of more than 1 liter occurred in 7.3% of the participants in the tranexamic acid group and in 8.0% of those in the placebo group (relative risk, 0.91; 95% CI, 0.79 to 1.05).

1197-18-8 Upstream products

  • 15177-68-1
    15177-68-1

    trans-4-cyanocyclohexane-1-ylcarboxylic acid

  • 19145-95-0
    19145-95-0

    methyl trans-4-cyanocyclohexane-1-carboxylate

  • 953817-12-4
    953817-12-4

    C12H17NO5

  • 1129-35-7
    1129-35-7

    4-cyanobenzoic acid methyl ester

1197-18-8 Downstream products

  • 41931-38-8
    41931-38-8

    4-(5-benzyl-6-thioxo-[1,3,5]thiadiazinan-3-ylmethyl)-cyclohexanecarboxylic acid

  • 23199-14-6
    23199-14-6

    4-aminomethyl-cyclohexanecarboxylic acid methyl ester

  • 102196-03-2
    102196-03-2

    methyl 3-propionate hydrochloride

  • 927869-66-7
    927869-66-7

    4-((2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-7-sulfonamido)methyl)cyclohexanecarboxylic acid

Relevant Products